Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Evaluate efficacy, ie, sustained virologic response 12 weeks after the end of treatment (SVR12), of a combination treatment with AL-335, ODV, and SMV for 6 and 8 weeks in chronic HCV genotype 1, 2, 4, 5, or 6 infected subjects without cirrhosis
Critère d'inclusion
- Chronic hepatitis C virus infection